Logo image of CYTK

CYTOKINETICS INC (CYTK) Stock Fundamental Analysis

NASDAQ:CYTK - Nasdaq - US23282W6057 - Common Stock - Currency: USD

37.23  -1.66 (-4.27%)

After market: 37.23 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CYTK. CYTK was compared to 558 industry peers in the Biotechnology industry. CYTK has a bad profitability rating. Also its financial health evaluation is rather negative. CYTK is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CYTK has reported negative net income.
In the past year CYTK has reported a negative cash flow from operations.
CYTK had negative earnings in each of the past 5 years.
In the past 5 years CYTK reported 4 times negative operating cash flow.
CYTK Yearly Net Income VS EBIT VS OCF VS FCFCYTK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200M -400M

1.2 Ratios

CYTK has a Return On Assets (-48.67%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -48.67%
ROE N/A
ROIC N/A
ROA(3y)-48.08%
ROA(5y)-38.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CYTK Yearly ROA, ROE, ROICCYTK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CYTK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CYTK Yearly Profit, Operating, Gross MarginsCYTK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

3

2. Health

2.1 Basic Checks

CYTK does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CYTK has been increased compared to 1 year ago.
Compared to 5 years ago, CYTK has more shares outstanding
CYTK has a better debt/assets ratio than last year.
CYTK Yearly Shares OutstandingCYTK Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CYTK Yearly Total Debt VS Total AssetsCYTK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

CYTK has an Altman-Z score of -2.06. This is a bad value and indicates that CYTK is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CYTK (-2.06) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.06
ROIC/WACCN/A
WACC9.42%
CYTK Yearly LT Debt VS Equity VS FCFCYTK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

2.3 Liquidity

A Current Ratio of 5.99 indicates that CYTK has no problem at all paying its short term obligations.
CYTK's Current ratio of 5.99 is fine compared to the rest of the industry. CYTK outperforms 61.65% of its industry peers.
CYTK has a Quick Ratio of 5.99. This indicates that CYTK is financially healthy and has no problem in meeting its short term obligations.
CYTK's Quick ratio of 5.99 is fine compared to the rest of the industry. CYTK outperforms 62.37% of its industry peers.
Industry RankSector Rank
Current Ratio 5.99
Quick Ratio 5.99
CYTK Yearly Current Assets VS Current LiabilitesCYTK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 1.48% over the past year.
CYTK shows a strong growth in Revenue. In the last year, the Revenue has grown by 411.53%.
Measured over the past years, CYTK shows a decrease in Revenue. The Revenue has been decreasing by -7.24% on average per year.
EPS 1Y (TTM)1.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.51%
Revenue 1Y (TTM)411.53%
Revenue growth 3Y-35.98%
Revenue growth 5Y-7.24%
Sales Q2Q%89.1%

3.2 Future

The Earnings Per Share is expected to grow by 18.93% on average over the next years. This is quite good.
The Revenue is expected to grow by 240.01% on average over the next years. This is a very strong growth
EPS Next Y-6.62%
EPS Next 2Y1.2%
EPS Next 3Y11.15%
EPS Next 5Y18.93%
Revenue Next Year613.56%
Revenue Next 2Y632.57%
Revenue Next 3Y406.62%
Revenue Next 5Y240.01%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CYTK Yearly Revenue VS EstimatesCYTK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
CYTK Yearly EPS VS EstimatesCYTK Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CYTK. In the last year negative earnings were reported.
Also next year CYTK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYTK Price Earnings VS Forward Price EarningsCYTK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYTK Per share dataCYTK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4 -5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.2%
EPS Next 3Y11.15%

More info and screens

0

5. Dividend

5.1 Amount

CYTK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYTOKINETICS INC

NASDAQ:CYTK (7/18/2025, 8:00:01 PM)

After market: 37.23 0 (0%)

37.23

-1.66 (-4.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)07-31 2025-07-31/amc
Inst Owners117.54%
Inst Owner Change0%
Ins Owners0.48%
Ins Owner Change1.81%
Market Cap4.45B
Analysts81.48
Price Target74.63 (100.46%)
Short Float %12.94%
Short Ratio8.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.1%
Min EPS beat(2)-3.56%
Max EPS beat(2)1.37%
EPS beat(4)1
Avg EPS beat(4)-7.65%
Min EPS beat(4)-21.59%
Max EPS beat(4)1.37%
EPS beat(8)1
Avg EPS beat(8)-22.14%
EPS beat(12)2
Avg EPS beat(12)-13.1%
EPS beat(16)3
Avg EPS beat(16)-9.6%
Revenue beat(2)2
Avg Revenue beat(2)440.89%
Min Revenue beat(2)28.69%
Max Revenue beat(2)853.1%
Revenue beat(4)2
Avg Revenue beat(4)186.56%
Min Revenue beat(4)-73.51%
Max Revenue beat(4)853.1%
Revenue beat(8)2
Avg Revenue beat(8)58.62%
Revenue beat(12)4
Avg Revenue beat(12)233.17%
Revenue beat(16)5
Avg Revenue beat(16)214.76%
PT rev (1m)0%
PT rev (3m)-6.05%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.19%
EPS NY rev (1m)0.44%
EPS NY rev (3m)4.16%
Revenue NQ rev (1m)0.7%
Revenue NQ rev (3m)100.5%
Revenue NY rev (1m)7.67%
Revenue NY rev (3m)-18.46%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 231.37
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.32
EYN/A
EPS(NY)-5.13
Fwd EYN/A
FCF(TTM)-3.41
FCFYN/A
OCF(TTM)-3.33
OCFYN/A
SpS0.16
BVpS-2.23
TBVpS-2.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -48.67%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.08%
ROA(5y)-38.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 100.74%
Cap/Sales 49.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.99
Quick Ratio 5.99
Altman-Z -2.06
F-Score5
WACC9.42%
ROIC/WACCN/A
Cap/Depr(3y)82.69%
Cap/Depr(5y)599.06%
Cap/Sales(3y)17.31%
Cap/Sales(5y)28.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.51%
EPS Next Y-6.62%
EPS Next 2Y1.2%
EPS Next 3Y11.15%
EPS Next 5Y18.93%
Revenue 1Y (TTM)411.53%
Revenue growth 3Y-35.98%
Revenue growth 5Y-7.24%
Sales Q2Q%89.1%
Revenue Next Year613.56%
Revenue Next 2Y632.57%
Revenue Next 3Y406.62%
Revenue Next 5Y240.01%
EBIT growth 1Y-13.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.79%
EBIT Next 3Y4.06%
EBIT Next 5Y24.98%
FCF growth 1Y-0.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-0.76%
OCF growth 3YN/A
OCF growth 5YN/A